Log in

Medigard Limited (MGZ.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Medigard Limited operates as a life sciences company in Australia. The company researches and develops medical technologies, including KT009 project to treat degenerative disk disease with an injectable product. Medigard Limited was founded in 1999 and is based in Main Beach, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars

Industry, Sector and Symbol

Industry Medical Instruments & Supplies
Phone61 7 5528 5640



Sales & Book Value

Annual Sales$623,740.00
Book ValueA$0.00 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive MGZ News and Ratings via Email

Sign-up to receive the latest news and ratings for MGZ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Medigard Limited (MGZ.AX) (ASX:MGZ) Frequently Asked Questions

Who are some of Medigard Limited (MGZ.AX)'s key competitors?

Who are Medigard Limited (MGZ.AX)'s key executives?

Medigard Limited (MGZ.AX)'s management team includes the following people:
  • Ms. Patricia Mary Boero, CFO & Company Sec.
  • Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D., Chairman of Scientific & Medical Advisory Panel and Exec. Director
  • Mr. Ross Joseph Cali, Head of Product Devel.

What is Medigard Limited (MGZ.AX)'s stock symbol?

Medigard Limited (MGZ.AX) trades on the ASX under the ticker symbol "MGZ."

How big of a company is Medigard Limited (MGZ.AX)?

Medigard Limited (MGZ.AX) has a market capitalization of $0.00 and generates $623,740.00 in revenue each year.

What is Medigard Limited (MGZ.AX)'s official website?

The official website for Medigard Limited (MGZ.AX) is www.medigard.com.au.

How can I contact Medigard Limited (MGZ.AX)?

The company can be reached via phone at 61 7 5528 5640.

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.